Cellular Biomedicine Group Profit Margin

The latest profit margin for CBMG is -16969.89% as of September 2020. That compares with -61118.98% in the prior-year period — up 72.2% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Cellular Biomedicine Group's historical trend and sector peers before judging valuation or financial health.

Over the past year, CBMG's profit margin moved from -61118.98% to -16969.89% — a 72.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cellular Biomedicine Group's valuation or profitability profile.

Against Healthcare companies, CBMG currently prints -16969.89% for profit margin, while the sector average sits near 13.89%. That is roughly 122246.4% below the sector mean. Large gaps often invite a closer look at Cellular Biomedicine Group's growth, margins, and balance sheet.

Profit Margin shows how effectively Cellular Biomedicine Group converts resources into returns. At -16969.89%, CBMG may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -61118.98% in the prior-year period — up 72.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CBMG's profit margin (-16969.89%), review year-over-year change from -61118.98%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.